Business Wire

LFB-SA

18.4.2016 15:39:14 CEST | Business Wire | Press release

Share
2015, a Strategic Year for LFB

Key events in 2015 :

  • Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
  • Two new products registered in Europe
  • Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
  • Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
  • Turnover of €502.4 million, stable in comparison to 2014

Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In 2015, the key milestones have been successfully achieved. It has been a historic and productive year for the future of LFB."

An unprecedented increase in capital in order to finance the group's development
As part of the group's strategic development, LFB's shareholder (the French State) decided in October to underwrite an increase in LFB's share capital by €230 million. The share capital of the company now stands at €280 million. To meet the financing needs of LFB's development project, on 5 January 2016 LFB issued a senior bond of €124 million. These funds will enable the construction of a 'new generation' plant in Arras. This flagship project, representing an investment of approximately €300 million, will enable LFB to triple its global production capacity in 2020 with facilities aimed at manufacturing for the whole world.
LFB is also developing its sites in Alès (Gard) and Charlton (USA), establishing bio-production facilities for recombinant medicines in development.

Consolidated earnings in €M

  2015   2014   Variation 2015/2014

Turnover

 

502.4

 

501.9

 

0.1 %

Gross margin

 

177.6

 

195.5

 

-9.2 %

Research & development

 

(81.3)

 

(65.9)

   

Commercial costs

 

(51.0)

 

(48.6)

 

General costs

 

(50.3)

 

(48.7)

 

Other charges and
operational income

 

17.0

 

(7.1)

 

Operational earnings

 

12.0

 

25.2

 

as a % of turnover

 

2.4 %

 

5.0 %

 

Net earnings

 

0.3

  13  

€90.5 million* before research tax credit

2015 turnover - growth in international sales
At €502.4 million, turnover is relatively stable as compared to 2014. For the second successive year, the group's turnover exceeded €500 million, with the international side business continuing to grow. Despite a 3.2 % decline in turnover in France during 2015, international sales rose by €12.1 million (+8.7%), reaching €152 million. This figure represents 30% of consolidated turnover (28% in 2014).

Operational earnings decline in order to finance strategy
Research and development costs are increasing rapidly (€81.3 million), owing to the large number of phase III trials in progress. Various strategic projects reached significant milestones. In 2015, two new LFB products, a 10% immunoglobulin and a fibrinogen have been subject to a mutual recognition in procedure in Europe with the Paul Ehrlich Institute as the referral agency. Two other recombinant products are currently at the end of phase III. At the same time, LFB is planning to manufacture product batches for launch, which has had an impact on earnings. In 2015, the group posted encouraging operational income (€17 million), notably owing to its holding in the bio-tech company TG Therapeutics Inc. The positive operational earnings (€12.0 million) is down as compared to that of 2014 (-13.2 million) due to a decline in gross margins and increased development costs. Despite this unprecedented effort, net earnings remain positive at €0.3 million.

About LFB Group
LFB is a bio-pharmaceutical company that develops, manufactures, and markets medicinal products from living systems for the treatment of serious and often rare diseases in the fields of Immunology, Hemostasis, Perinatal, and Intensive Care. Currently ranked 6th worldwide in the field of plasma-derived medicinal products, LFB Group is also among the leading European companies in the development and production of proteins and innovative treatments derived from bio-technologies. It employs 2,111 staff worldwide.
http://www.groupe-lfb.fr

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Contact:

LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication Director
charrieres@lfb.fr
or
David Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Open Group Launches the Open Footprint® Standard, Edition 1.0 to Streamline Scope 1, 2, and 3 Emissions Management2.6.2026 09:00:00 CEST | Press release

The Open Group, the vendor-neutral technology and standards organization, today announced the release of the Open Footprint® Standard, Edition 1.0, that will help organizations streamline scope 1, 2, and 3 emissions reporting. The new standard is the first open emissions data model to address all three scopes, providing a comprehensive framework that enables organizations to collect and standardize data from their value chain and report across multiple jurisdictions. “There is an urgent need to streamline emissions data management and reduce the manual effort required to capture data within supply chains, perform data conversion, and report out to various regulators,” said Steve Nunn, President and CEO of The Open Group. “The Open Footprint Standard removes friction and lowers cost, helping organizations identify emissions reduction opportunities.” Key features of the model include: Standardized emissions data definitions and relationships Simplified emissions data sharing and interope

Thredd Renews and Expands Partnership with Caxton2.6.2026 09:00:00 CEST | Press release

Five-year renewal and strategic expansion strengthens travel, corporate, and parent-child card innovation Thredd, the AI-first issuer processing platform, today announced a five-year renewal and strategic programme expansion with Caxton, the leading payments solutions provider, reinforcing Thredd’s role as the company’s primary issuer-processor across consumer and corporate cards. Caxton, a leading UK payments provider, has partnered with Thredd since 2020 to power its multi-currency prepaid travel and expense cards. Customers can hold up to 15 currencies on a single card. As part of the renewed agreement, Thredd will bring Caxton’s parent-child card programme, nimbl, onto the Thredd platform. All nimbl customers will be re-carded as the programme is launched using Thredd’s infrastructure, with completion targeted before the end of the year. nimbl is a financial education-focused debit card designed for children aged 6–16, enabling parents to manage allowances and teach money managemen

Medscape Brings AI to the Hematology Frontline at EHA 20262.6.2026 08:00:00 CEST | Press release

Landmark symposium to equip clinicians with practical, ethical AI frameworks, chaired by a lead author of Europe's ESMO EBAI and ELCAP oncology guidelines. Medscape Education will launch Future-Ready Hematologists: Practical and Ethical Use of AI in Hematology and Oncology at EHA 2026 on June 11, where leading experts will convene to explore responsible AI in one of medicine's most complex, rapidly evolving specialties. Registration is free for all EHA delegates. Reserve your seat here. The session is chaired by Prof. Jakob N. Kather, MD, MSc, Else Kroener Fresenius Center for Digital Health, Technical University Dresden, and NCT, University Hospital Heidelberg. He is joined by Prof. Chan Cheah, MBBS, DMSc, Consultant Hematologist, Sir Charles Gairdner Hospital, Perth, Australia; and Prof. Matthew Lunning, DO, FACP, Chief of Hematology and Assistant Vice Chancellor of Research, University of Nebraska Medical Center. Hematology moves faster than any clinician can track alone. AI can clo

Signaloid Announces Preview of New ASIC Targeted at Physical AI and Robotics Applications2.6.2026 06:00:00 CEST | Press release

Signaloid previews a new ASIC purpose-built for physical AI and robotics workloads.The chip, taped out with TSMC in partnership with IC-Link by imec and Cadence, is projected to deliver up to 1000× better performance-per-watt in key physical AI workloads. Signaloid (https://signaloid.com), a computing platform company providing hardware and binary-translation-based acceleration of AI, robotics, aerospace, and quantitative finance workloads, today announced the tapeout and preliminary specifications documents for its C0-ASIC. Delivery of engineering samples to the first customer is due in Q3 2026 and additional FPGA-based systems implementing the ASIC’s design are under discussion for deployment in the UK and Switzerland later in 2026. The C0-ASIC was targeted specifically at energy-efficient physical AI workloads. The UK Advanced Research and Invention Agency (ARIA) will take delivery of systems based on the ASIC for use in next-generation AI workloads such as second order methods. “Th

Blackstone Raises its Largest Asia Private Equity Fund at $13.1 Billion2.6.2026 03:00:00 CEST | Press release

Oversubscribed Fund More than Doubles Capital Raised for Predecessor Vehicle Blackstone (NYSE: BX) today announced the final close of Blackstone Capital Partners Asia III (“BCP Asia III”) at $13.1 billion, exceeding its $10 billion target and marking the firm’s largest private equity fundraise in the region. The oversubscribed fund reached its hard cap and builds on the strong performance of the strategy’s first two vintages, with this close representing more than double the amount of capital raised for its predecessor vehicle. Joe Baratta, Global Head of Blackstone Private Equity Strategies,said: “We are grateful for the continued trust of our investors in Blackstone and our leading Asia Private Equity franchise. This successful fundraise reflects the strength of our platform and our ability to perform through cycles. Asia Pacific is the fastest-growing region in the world, presenting compelling opportunities to invest at scale behind our high-conviction themes and deliver for our inv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye